Literature DB >> 19364959

UGT1A and irinotecan toxicity: keeping it in the family.

Janelle M Hoskins, Howard L McLeod.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19364959     DOI： 10.1200/JCO.2008.20.9478

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

Review 1.  Irinotecan pharmacogenomics.

Authors:  Sharon Marsh; Janelle M Hoskins
Journal:  Pharmacogenomics       Date:  2010-07       Impact factor: 2.533

2.  A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors.

Authors:  Nai-Jung Chiang; Tsu-Yi Chao; Ruey-Kuen Hsieh; Cheng-Hsu Wang; Yi-Wen Wang; C Grace Yeh; Li-Tzong Chen
Journal:  BMC Cancer       Date:  2016-11-21       Impact factor: 4.430

3.  Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients.

Authors:  Martina Rebersek; Tanja Mesti; Marko Boc; Janja Ocvirk
Journal:  Radiol Oncol       Date:  2019-03-03       Impact factor: 2.991

4.  Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians.

Authors:  Xiang Liu; Dangxiao Cheng; Qin Kuang; Geoffrey Liu; Wei Xu
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.